Page 29 - 2019_02-Haematologica-web

CD30+ primary cutaneous LPD
and checkpoint inhibitors in MF patients.110 MiR-155 is also upregulated in pcALCL,77 providing an additional therapeutic opportunity for these tumors.
Acknowledgments
Funding
This work was supported by grants from the Instituto de Salud Carlos III (ISCIII) of the Spanish Ministry of Economy and Competence (MINECO, RTICC ISCIII and CIBERONC) (SAF2013-47416-R, RD06/0020/0107-RD012/0036/0060
Amaia Alzelai, Salma Machan, Victor Alegre and David and Plan Nacional I+D+I: PI17/2172, PI16/01294 and
Lapeña provided cases and inspiration.
References
1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
2. Taylor J, Xiao W, Abdel-Wahab O. Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. 2017;130(4):410-423.
3. MacaulayWL.Lymphomatoidpapulosis.A continuing self-healing eruption, clinically benign--histologically malignant. Arch Dermatol. 1968;97(1):23-30.
4. Nijsten T, Curiel-Lewandrowski C, Kadin ME. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. Arch Dermatol. 2004;140(3):306-312.
5. Kempf W. A new era for cutaneous CD30- positive T-cell lymphoproliferative disor- ders. Semin Diagn Pathol. 2017;34(1):22-35.
6. Kempf W, Mitteldorf C, Karai LJ, et al. Lymphomatoid papulosis - making sense of the alphabet soup: a proposal to simplify terminology. J Dtsch Dermatol Ges. 2017;15(4):390-394.
7. BekkenkMW,GeelenFA,vanVoorstVader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow- up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95(12):3653-3661.
8. Saggini A, Gulia A, Argenyi Z, et al. A vari- ant of lymphomatoid papulosis simulating primary cutaneous aggressive epider- motropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases. Am J Surg Pathol. 2010;34(8):1168-1175.
9. Kempf W, Kazakov DV, Scharer L, et al. Angioinvasive lymphomatoid papulosis: a new variant simulating aggressive lym- phomas. Am J Surg Pathol. 2013;37(1):1-13.
10. Karai LJ, Kadin ME, Hsi ED, et al. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol. 2013;37(8): 1173-1181.
11. Wada DA, Law ME, Hsi ED, et al. Specificity of IRF4 translocations for pri- mary cutaneous anaplastic large cell lym- phoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011;24(4):596-605.
12. Greisser J, Palmedo G, Sander C, et al. Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disor- ders. J Cutan Pathol. 2006;33(11):711-715.
13. Chott A, Vonderheid EC, Olbricht S, et al. The dominant T cell clone is present in mul- tiple regressing skin lesions and associated T
PIE15/0081), AECC and the Madrid Autonomous Community.
26. Kamstrup MR, Ralfkiaer E, Skovgaard GL, et al. Potential involvement of Notch1 sig- nalling in the pathogenesis of primary cuta- neous CD30-positive lymphoproliferative disorders. Br J Dermatol. 2008;158(4):747-
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
cell lymphomas of patients with lym-
phomatoid papulosis. J Invest Dermatol. 1996;106(4):696-700.
de la Garza Bravo MM, Patel KP, Loghavi S,
et al. Shared clonality in distinctive lesions
of lymphomatoid papulosis and mycosis 753.
fungoides occurring in the same patients suggests a common origin. Hum Pathol. 2015;46(4):558-569.
Rodriguez-Pinilla SM, Ortiz-Romero PL, Monsalvez V, et al. TCR-gamma expression in primary cutaneous T-cell lymphomas. Am J Surg Pathol. 2013;37(3):375-384. Yasui D, Miyano M, Cai S, et al. SATB1 tar- gets chromatin remodelling to regulate genes over long distances. Nature. 2002;419(6907):641-645.
Alvarez JD, Yasui DH, Niida H, et al. The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes Dev. 2000;14(5):521-535.
Wang Y, Su M, Zhou LL, et al. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription. Blood. 2011;117 (14):3826-3835.
Sun J, Yi S, Qiu L, et al. SATB1 defines a sub- type of cutaneous CD30(+) lymphoprolifer- ative disorders associated with a T-helper 17 cytokine profile. J Invest Dermatol. 2018;138(8):1795-1804.
Durkop H, Hirsch B, Hahn C, et al. Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation. J Pathol. 2003;200(2):229-239.
Assaf C, Hirsch B, Wagner F, et al. Differential expression of TRAF1 aids in the distinction of cutaneous CD30-positive lymphoproliferations. J Invest Dermatol. 2007;127(8):1898-1904.
Benner MF, Jansen PM, Meijer CJ, et al. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lym- phoproliferative disorders. Br J Dermatol. 2009;161(1):121-127.
Mathas S, Kreher S, Meaburn KJ, et al. Gene deregulation and spatial genome reorgani- zation near breakpoints prior to formation of translocations in anaplastic large cell lym- phoma. Proc Natl Acad Sci USA. 2009;106 (14):5831-5836.
Cotta CV, Leventaki V, Atsaves V, et al. The helix-loop-helix protein Id2 is expressed dif- ferentially and induced by Myc in T-cell lymphomas. Cancer. 2008;112(3):552-561. Kapur S, Tiemann M, Menke MA, et al. The role of p53 and anaplastic lymphoma kinase genes in the progression of cutaneous CD30(+) lymphoproliferative diseases. Indian J Med Res. 2005;121(1):46-54.
27. Vasmatzis G, Johnson SH, Knudson RA, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lym- phomas. Blood. 2012;120(11):2280-2289.
28. Schrader AM, Chung YY, Jansen PM, et al. No TP63 rearrangements in a selected group of primary cutaneous CD30+ lymphoprolif- erative disorders with aggressive clinical course. Blood. 2016;128(1):141-143.
29. Fornari A, Piva R, Chiarle R, et al. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? Hematol Oncol. 2009;27(4):161-170.
30. Xing X, Feldman AL. Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous. Adv Anat Pathol. 2015;22(1):29-49.
31. Laharanne E, Oumouhou N, Bonnet F, et al. Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically rele- vant classes. J Invest Dermatol. 2010;130(6): 1707-1718.
32. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical fea- tures. Blood. 2000;96(12):3681-3695.
33. Kerschmann RL, Berger TG, Weiss LM, et al. Cutaneous presentations of lymphoma in human immunodeficiency virus disease. Predominance of T cell lineage. Arch Dermatol. 1995;131(11):1281-1288.
34. Yurtsever H, Kempf W, Laeng RH. Posttransplant CD30+ anaplastic large cell lymphoma with skin and lymph node involvement. Dermatology. 2003;207(1): 107-110.
35. Benner MF, Willemze R. Applicability and prognostic value of the new TNM classifica- tion system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol. 2009;145(12):1399-1404.
36. Woo DK, Jones CR, Vanoli-Storz MN, et al. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characteri- zation of clinical subset with worse out- come. Arch Dermatol. 2009;145(6):667-674.
37. Burg G, Kempf W, Kazakov DV, et al. Pyogenic lymphoma of the skin: a peculiar variant of primary cutaneous neutrophil- rich CD30+ anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literature. Br J Dermatol. 2003;148(3):580-586.
38. Massone C, El-Shabrawi-Caelen L, Kerl H, et al. The morphologic spectrum of primary cutaneous anaplastic large T-cell lymphoma: a histopathologic study on 66 biopsy speci-
haematologica | 2019; 104(2)
233